Immune activation and virologic response to immunization in recent HIV type 1 seroconverters

AIDS Research and Human Retroviruses

Volumn 15, Issue 9, 1999, Pages 837-845

  Janoff, Edward N ^a,d   Tasker, Sybil A ^b   Stevenson, Mario ^c   Rubins, Jeffrey B ^a   O'Brien, James ^a   Utz, Greg ^b   Weiss, Peter ^b   Hall, Frank W ^b   Wallace, Mark R ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIPHTHERIA TOXOID; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; LAMIVUDINE; PNEUMOCOCCUS VACCINE; STAVUDINE;

ADULT; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; SEROCONVERSION; T LYMPHOCYTE ACTIVATION; VACCINATION; VIRUS INFECTION;

EID: 0033033384     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299310746     Document Type: Article

References (57)

1. Krumholz HM, Sande MA, and Lo B: Community-acquired bacteremia in patients with acquired immunodeficiency syndrome: Clinical presentation, bacteriology and outcome. Am J Med 1989;86:776-779.
2. Janoff EN, Breiman RF, Daley CL, and Hopewell PC: Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives. Ann Intern Med 1992;117:314-324.
3. Mundy LM, Auwaerter PG, Oldach D, Warner ML, Burton A, Vance E, Gaydos CA, Joseph JM, Gopalan R, Moore RD, Quinn TC, Charache P, and Bartlett JG: Community-acquired pneumonia: Impact of immune status. Am J Respir Crit Care Med 1995; 152:1309-1315.
4. Hirschtick RE, Glassroth J, Jordan MC, Wilcosky TC, Wallace JM, Kvale PA, Markowitz N, Rosen MJ, Mangura BT, and Hopewell PC: Bacterial pneumonia in persons infected with the human immunodeficiency virus. N Engl J Med 1995;33:845-851.
5. Selwyn PA, Alcabes P, Hartel D, Buono D, Schoenbaum EE, Klein RS, Davenny K, and Friedland GH: Clinical manifestation and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med 1992;327:1697-1703.
6. Mellors JW, Kingsley LA, Rinaldo CRJ, Todd JA, Hoo BS, Kokka RP, and Gupta P: Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-579.
7. + lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;7:426-431.
8. Bush CE, Donovan RM, Markowitz NP, Kvale P, and Saravolatz LD: A study of HIV RNA viral load in AIDS patients with bacterial pneumonia. J Acquir Immune Defic Syndr 1996;13:23-26.
9. American College of Physicians Task Force on Adult Immunization and Infectious Diseases Society of America: Guide for Adult Immunization, 3rd ed. American College of Physicians, Philadelphia, 1994.
10. Advisory Committee on Immunization Practices (ACIP): Prevention and control of influenza: Recommendations of the ACIP. Centers for Disease Control and Prevention. MMWR 1995;44:1-22.
11. Brichacek B, Swindells S, Janoff EN, Pirruccello S, and Stevenson M: Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J Infect Dis 1996;174:1191-1199.
12. Stanley SK, Ostrowski MA, Justement JS, Gantt K, Hedayati S, Mannix M, Roche K, Schwartzentruber DJ, Fox CH, and Fauci AS: Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med 1996;334:1222-1230.
13. O'Brien WA, Grovit-Ferbas K, Namazi A, Ovcak-Derzic S, Wang H-J, Park J, Yeramian C, Mao S-H, and Zack JA: Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995;86:1082-1089.
14. Staprans SI, Hamilton BL, Follansbee SE, Elbeik T, Barbosa P, Grant RM, and Feinberg MB: Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 1995; 182:1727-1737.
15. Stevenson M, Stanwick TL, Dempsey MP, and Lamonica CA: HIV-1 replication is controlled at the level of T cell activation and proviral integration. Eur Mol Biol Organ J 1990;9:1551-1560.
16. Weiss PJ, Wallace MR, Oldfield EC III, O'Brien J, and Janoff EN: Response of recent HIV-seroconverters to the pneumococcal polysaccharide vaccine and Haemophilus influenzae type be conjugate vaccine. J Infect Dis 1995;171:1217-1222.
17. Garland FC, Mayers DL, Hickey TM, et al.: Incidence of human immunodeficiency virus seroconversion in US Navy and Marine Corps personnel, 1986 through 1988. JAMA 1989;262:3161-3165.
18. + natural killer cell subset during HIV infection. Cytometry 1995;22:10-15.
19. Baker PJ: T cell regulation of the antibody response to bacterial polysaccharide antigens: An examination of some general characteristics and their implications. J Infect Dis 1992;165(Suppl. 1):S44-S48.
20. Mond JJ, Lees A, and Snapper CM: T cell-independent antigens type 2. Annu Rev Immunol 1995;13:655-695.
21. Schnittman SM, Psallidopoulos MC, Lane HC, Thompson L, Baseler M, Massari F, Fox CH, Salzman NP, and Fauci AS: The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science 1989;245:361-367.
22. Schacker TW, Hughes JP, Shea T, Coombs RW, and Corey L: Biological and virologic characteristics of primary HIV infection. Ann Intern Med 1998;128:613-620.
23. Redd SC, Rutherford GW, Sande MA, Lifson AR, Hadley WK, Facklam RR, and Spika JS: The role of human immunodeficiency virus in pneumococcal bacteremia in San Francisco residents. J Infect Dis 1990;162:1012-1017.
24. Gilks CF, Ojoo SA, Ojoo JC, Brindle RJ, Paul J, Batchelor BIF, Kimari JN, Newnham R, Bwayo J, Plummer FA, and Warrell DA: Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya. Lancet 1996; 347:718-723.
25. Janoff EN and Rubins JB: Invasive pneumococcal disease in the immunocompromised host. Microbial Drug Resist 1997;3: 215-232.
26. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K, and Haase AT: Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature (London) 1993;362:359-362.
27. Levy JA: HIV and the Pathogenesis of AIDS. American Society for Microbiology, Washington, D.C., 1994.
28. + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986;234:1563-1566.
29. + T cells. Science 1995;270:1811-1815.
30. Fauci AS: Multifactorial nature of human immunodeficiency virus disease: Implications for therapy. Science 1993;262:1011-1018.
31. Xiao L, Owen SM, Rudolph DL, Lal RB, and Lal AA: Plasmodium falciparum antigen-induced human immunodeficiency virus type 1 replication is mediated through induction of tumor necrosis factor-α. J Infect Dis 1998;177:437-445.
32. Musey L, Hughes J, Schacker TW, Shea T, Corey L, and McElrath JJ: Cytotoxic-T-cell responses, viral load and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997;337:1267-1274.
33. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, and Ho DD: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650-4655.
34. + T cells is markedly enhanced in the setting of antigen-specific immune activation. J Exp Med 1996;183:687-692.
35. Stevenson M, Bukrinsky M, and Haggerty S: HIV-1 replication and potential targets for intervention. AIDS Res Hum Retroviruses 1992;8:107-117.
36. Bukrinsky MI, Stanwick TL, Dempsey MP, and Stevenson M: Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 1991;254:423-427.
37. Orenstein JM, Fox C, and Wahl SM: Macrophages as a source of HIV during opportunistic infections. Science 1997;276:1857-1861.
38. Dockrell DH, Poland GA, Mitchell PS, Wollan PC, Smith TF, Persing DH, Strickland SR, and Pomeroy C: Effect of Haemophilus influenzae type B immunization on HIV viremia in HIV-seropositive adults. J Acquir Immune Defic Syndr 1998;18:512-513. [Letter]
39. H0 cells. Science 1994; 265:244-248.
40. + T cells producing Th2-type cytokines. FASEB J 1995;9:81-86.
41. Del Prete G, Maggi E, Pizzolo G, and Romagnani S: CD30, Th2 cytokines and HIV infection: A complex and fascinating link. Immunol Today 1995;16:76-80.
42. Poli G and Fauci AS: The effect of cytokines and pharmacologic agents on chronic HIV infection. AIDS Res Hum Retroviruses 1991;8:191-197.
43. D'Amico R, Fowke K, Chernoff D, Pottage J, Benson C, Sha B, Landay A, Shearer G, and Kessler H: Virologic/immunologic effects of influenza immunization on HIV-1 infected patients. In: The 34th Annual Infectious Diseases of America Meeting, New Orleans, LA, 1996. [Abstract 258]
44. Glesby MJ, Hoover DR, Farzadegan H, Margolick JB, and Saah AJ: The effect of influenza vaccination on human immunodeficiency virus type 1 load: A randomized, double-blind, placebo-controlled study. J Infect Dis 1996;174:1332-1336.
45. Reboli AC, Palmer A, Byrne B, McCoy P, Chernoff D, and Baxter JD: Influenza vaccination has no effect on viral load in HIV-infected patients with higher CD4 counts. In: The 34th Annual Infectious Diseases Society of America Meeting, New Orleans, LA, 1996. [Abstract 257]
46. Kroon FP, Van Furth R, and Bruisten SM: The effects of immunization in human immunodeficiency virus type 1 infection. N Engl J Med 1996;335:817-818. [Letter]
47. Ho DD: HIV-1 viraemia and influenza. Lancet 1992;339:1549.
48. Goletti D, Weissman D, Jackson RW, Graham NMH, Vlahov D, Klein RS, Munsiff SS, Ortona L, Cauda R, and Fauci AS: Effect of Mycobacterium tuberculosis on HIV replication. J Immunol 1996;157:1271-1278.
49. Donovan RM, Bush CE, Markowitz NP, Baxa DM, and Saravolatz LD: Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons. J Infect Dis 1996;174:401-403.
50. Denis M and Ghadirian E: Mycobacterium avium infection in HIV-1-infected subjects increases monokine secretion and is associated with enhanced viral load and diminished immune response to viral antigens. Clin Exp Immunol 1994;97:76-82.
51. Pape JW, Jean SS, Ho JL, Hafner A, and Johnson WD Jr: Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993;342:268-272.
52. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkoff M, and Ellner J: Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995; 151:129.
53. Hibbs JR, Douglas JM Jr, Judson FN, McGill WL, Rietmeijer CAM, and Janoff EN: Prevalence of human immunodeficiency virus infection, mortality rate, and serogroup distribution among patients with pneumococcal bacteremia at Denver General Hospital, 1984-1994. Clin Infect Dis 1997;25:195-199.
54. Crewe-Brown HH, Karstaedt AS, Saunders GL, Khoosal M, Jones N, Vasas A, and Klugman KP: Streptococcus pneumoniae blood culture isolates from patients with and without human immunodeficiency virus infection: Alterations in penicillin susceptibilities and in serogroups or serotypes. Clin Infect Dis 1997;25:1165-1172.
55. Ward JW, Hanson DL, Jones J, and Kaplan JON: Pneumococcal vaccination and the incidence of pneumonia among HIV-1-infected persons. Clin Infect Dis 1996;23:905. [Abstract]
56. Steinhoff MC, Auerbach BS, Nelson K, Vlahov D, Becker RL, Graham NM, Schwartz DH, Lucas AH, and Chaisson RE: Antibody responses to Haemophilus influenzae type b vaccines in men with human immunodeficiency virus infection. N Engl J Med 1991;325:1837-1842.
57. Cheeseman SH, Davaro RE, and Ellison RT III: Hepatitis B vaccination and plasma HIV-1 RNA. N Engl J Med 1996;334:1272. [Letter]